Venture report: Frontier enters clinic with $80M round; ORI’s new $260M fund

As it announced its new $80 million series C round, Frontier Medicines Corp. revealed that it has begun dosing patients in its first clinical study of lead candidate FMC-376, a dual KRAS G12C inhibitor.

Led by Deerfield Management and Droia Ventures, the round brings Frontier’s total equity capital investment to $235.5 million thus far. Its new Phase I/II PROSPER trial of FMC-376 to treat KRAS G12C cancers will be the first clinical test of a therapy derived from its platform, with which the company aims to address previously undruggable targets using small molecules that reach transient “hotspot” binding pockets...